Happy Friday! Elizabeth Cooney here from Boston, filling in for Ed Silverman from a campus that the no-longer-short people long ago fled to ply their trades in New York, where the mascots are feline, and in which the coffee is never flavored (and always black). Ed will be back in the Pharmalot castle next week. Thank you for all your comments and tips this week. Here are some more items to ponder:

A little more than a week ago, Amarin (AMRN) said that the Food and Drug Administration was “unlikely” to convene an advisory committee meeting to review data on an expanded use of its heart drug Vascepa, STAT says. But on Thursday, Amarin reversed course, announcing that the FDA has scheduled a Vascepa advisory committee meeting for Nov. 14, raising fears that something might be amiss with the Vascepa clinical trial data.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy